|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02335 MICOT PHARMA-B
Nominal 
() | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | |
| Turnover | 0 | -- | 0 |
| Cost of Sales | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | |
| Other Non-operating Items | (9,901) | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | |
| Profit / (Loss) before Taxation | (184,914) | 17.924% | (156,808) | |
| Taxation | 0 | -- | (24) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | |
| Non-controlling Interests | 2,407 | 9.409% | 2,200 | |
| Others | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (182,507) | 18.027% | (154,632) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 64,995 | 88.879% | 34,411 |
| Depreciation & Amortisation | 6,574 | -21.626% | 8,388 |
| Directors' Emoluments | 3,344 | -1.357% | 3,390 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | |
| EPS (cts) | -- | -- | -- |
| DPS (cts) | -- | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- |
| NBV per share ($) | -- | -- | -- |
| Remarks: | Real time quote last updated: 16/06/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -182,507 |
| %Change | 18.027% |
| EPS / (LPS) | RMB -- |
| NBV Per Share (¥) | RMB -- |